Journal: Molecular Vision

Article Title: Ex vivo expanded SSEA-4+ human limbal stromal cells are multipotent and do not express other embryonic stem cell markers

doi:

Figure Lengend Snippet: Expression profiles of limbal stromal (LS) at passage 6 and corneal stromal (CS) cells at passage 4 by FACS analysis. The two populations of cells have very similar expression where they expressed mesenchymal markers and absence of hematopoietic markers and endothelial marker (CD31). The cells did not express ABCG2 and other embryonic stem cells markers. The green line in the histograms represents the isotype controls.

Article Snippet: Embryonic stem cell line, BG01V (ATCC) at passage 16 were cultured on mitomycin treated MEF cells (ATCC) with 80% knockout DMEM supplemented with 20% Gibco knockout SR, 1% MEM-non essential amino acid (NEAA), 1% Glutamax, 0.1 mM B-mercaptoethanol (BME), 10 IU/ml penicillin, 10 μg/ml streptomycin (all from Invitrogen Corporation), and 4 ng/ml human basic fibroblast growth factor (bFGF; BD Biosciences) [ ].

Techniques: Expressing, Marker

Journal: PLoS ONE

Article Title: Vaccination with Embryonic Stem Cells Protects against Lung Cancer: Is a Broad-Spectrum Prophylactic Vaccine against Cancer Possible?

doi: 10.1371/journal.pone.0042289

Figure Lengend Snippet: ( A ) Bar graph showing GM-CSF expression in non-transduced and retrovirally transduced STO fibroblasts. Error bars represent mean ± SD. *, p<0.05; relative to non-transduced STO cells; t test. ( B ) Scheme of immunization. Male C57BL/6 mice were immunized twice (days 0 and 14) with HBSS (control), or irradiated 1×10 6 ESC+irradiated 1×10 6 GM-CSF-expressing STO murine embryonic fibroblasts (STO-GM) s.c. in the right flank. Seven days after boost, mice were challenged with 1×10 5 Lewis lung carcinoma cells (LLC) s.c. in the left flank. ( C ) C57BL/6 mice (10/group) were immunized twice (days 0 and 14) with HBSS (control), or irradiated 1×10 6 ESC+irradiated 1×10 6 STO-GM, or irradiated 1×10 6 STO-GM cells alone s.c. in the right flank prior to s.c. challenge with LLC on day 21. Tumor growth was monitored daily in all animals until sacrifice due to tumors exceeding 5% of body weight. The vaccinated tumor free mice remained so for up to 4 months later with no overt signs of distress or autoimmunity. are representative of three independent experiments. **, p <0.001; relative to control group; log-rank test. ( D ). Tumor growth was measured by calipers every 2nd or 3rd day and tumor volumes were plotted as indicated. The data represent the average tumor volumes of 10 mice/control group and 3 mice/ESC/STO-GM group and are representative of three independent experiments. Error bars represent mean ± SEM.

Article Snippet: As a vaccine, we employed the murine embryonic stem cell (ESC) line, ES-D3 (ATCC CRL-11632), derived from 129/Sv mice (expressing MHC class II I-E).

Techniques: Expressing, Control, Irradiation

Journal: International review of neurobiology

Article Title: Cell transplantation to repair the injured spinal cord

doi: 10.1016/bs.irn.2022.09.008

Figure Lengend Snippet: Transplantation of tissues and cells to provide novel neuronal connections & an anatomical relay for spinal cord repair.

Article Snippet: S.Biomedics Co., Ltd. (Korea) , Neural precursor cells derived from human embryonic stem cell line , 18–65 y.o. SCI at C4-C7 level; AIS A , 7–60 days post-injury , Phase I and II , Safety; sensory and motor function evaluated with AIS, ISNCSCI, and SCIM scores , 2021–2028 , 5 , NCT04812431.

Techniques: Transplantation Assay, Suspension, Cell Culture

Journal: International review of neurobiology

Article Title: Cell transplantation to repair the injured spinal cord

doi: 10.1016/bs.irn.2022.09.008

Figure Lengend Snippet: Transplantation of tissues and cells to provide neuroprotection of spinal cord tissue.

Article Snippet: S.Biomedics Co., Ltd. (Korea) , Neural precursor cells derived from human embryonic stem cell line , 18–65 y.o. SCI at C4-C7 level; AIS A , 7–60 days post-injury , Phase I and II , Safety; sensory and motor function evaluated with AIS, ISNCSCI, and SCIM scores , 2021–2028 , 5 , NCT04812431.

Techniques: Transplantation Assay, Derivative Assay, Cell Culture

Journal: International review of neurobiology

Article Title: Cell transplantation to repair the injured spinal cord

doi: 10.1016/bs.irn.2022.09.008

Figure Lengend Snippet: Clinical trials transplanting tissue and cells for spinal cord repair.

Article Snippet: S.Biomedics Co., Ltd. (Korea) , Neural precursor cells derived from human embryonic stem cell line , 18–65 y.o. SCI at C4-C7 level; AIS A , 7–60 days post-injury , Phase I and II , Safety; sensory and motor function evaluated with AIS, ISNCSCI, and SCIM scores , 2021–2028 , 5 , NCT04812431.

Techniques: Clinical Proteomics, Modification, Derivative Assay, Transplantation Assay, Functional Assay, Control, Cell Culture

Journal: International review of neurobiology

Article Title: Cell transplantation to repair the injured spinal cord

doi: 10.1016/bs.irn.2022.09.008

Figure Lengend Snippet: Schematic diagram highlighting potential sources of neural stem and precursor cells: the developing neural tissues (A), pluripotent embryonic stem cells (B), and induced pluripotent stem cells (C; exemplified by skin fibroblast de-differentiation/reprogramming). These cells can be engineered to produce neural stem and progenitor cells that can then be expanded (D), specific subsets selected (e.g., NRPs and GRPs), and cryopreserved for “cell banking.” These cell stores can be thawed and prepared for transplantation into the injured spinal cord (E) alone, or in combination with additional treatments (E), including rehabilitation and activity-based therapy, neural interfacing and neuromodulation, application of scaffolds/biomaterials, or additional pharmaceuticals to enhance efficacy. Figure modified from Zholudeva, L. V., & Lane, M. A. (2022). Spinal interneurons: Plasticity after spinal cord injury, 1st ed. Academic Press.

Article Snippet: S.Biomedics Co., Ltd. (Korea) , Neural precursor cells derived from human embryonic stem cell line , 18–65 y.o. SCI at C4-C7 level; AIS A , 7–60 days post-injury , Phase I and II , Safety; sensory and motor function evaluated with AIS, ISNCSCI, and SCIM scores , 2021–2028 , 5 , NCT04812431.

Techniques: Transplantation Assay, Activity Assay, Modification

Journal: Cell Reports Methods

Article Title: Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy

doi: 10.1016/j.crmeth.2024.100843

Figure Lengend Snippet: Expression of T cell signature genes in hPSC-derived T lineage cells (A) Uniform manifold approximation and projection (UMAP) representation of the T56 ATO T cell induction system containing T lineage, ILC lineage, mast cell lineage, and a small number of undefined clusters that did not resemble any in vivo cell type. Results from the hESC line H1 are shown. (B) Lineage-specific marker gene expression patterns in each cluster. (C) TCR + and TCR − cell distributions in the T56 ATO T cell induction system. (D) T cell signature and NK cell signature gene expression patterns in TCR + cells from the T56 ATO T cell induction system. See also Figures S2 and .

Article Snippet: human embryonic stem cell line H1 , iCell Bioscience Inc. , Cat#iCell-h299.

Techniques: Expressing, Derivative Assay, In Vivo, Marker, Gene Expression

Journal: Cell Reports Methods

Article Title: Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy

doi: 10.1016/j.crmeth.2024.100843

Figure Lengend Snippet: Expression of typical T cell signature genes and NK cell signature genes in hPSC-derived iTNK cells (A) TCR + and TCR − cell distributions in hPSC-derived iTNK cells. Results from the hESC line H1 are shown. (B) Lineage-specific marker gene expression patterns in TCR + and TCR − cells. (C) T cell signature and NK cell signature gene expression patterns in TCR + iTNK cells. See also Figures S4 and .

Article Snippet: human embryonic stem cell line H1 , iCell Bioscience Inc. , Cat#iCell-h299.

Techniques: Expressing, Derivative Assay, Marker, Gene Expression

Journal: Cell Reports Methods

Article Title: Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy

doi: 10.1016/j.crmeth.2024.100843

Figure Lengend Snippet: TCR repertoires and differences in expression of hPSC-derived T lineage cells and iTNK cells (A) CDR3 length distributions of hPSC-derived T lineage cells. Results from the hESC line H1 are shown. (B) CDR3 length distributions of hPSC-derived iTNK cells. Results from the hESC line H1 are shown. (C) TCR V-gene usage among hPSC-derived T lineage cells. (D) TCR V-gene usage among hPSC-derived iTNK cells. (E) Gene Ontology enrichment of upregulated genes in TCR + iTNK cells compared with TCR + T lineage cells. (F) Trajectory analysis of the cells in ATO system and iTNK cells. See also Figures S6–S8 .

Article Snippet: human embryonic stem cell line H1 , iCell Bioscience Inc. , Cat#iCell-h299.

Techniques: Expressing, Derivative Assay

Journal: Cell Reports Methods

Article Title: Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy

doi: 10.1016/j.crmeth.2024.100843

Figure Lengend Snippet:

Article Snippet: human embryonic stem cell line H1 , iCell Bioscience Inc. , Cat#iCell-h299.

Techniques: Staining, Purification, Recombinant, Modification, Membrane, Cell Stimulation, Wright Stain, Software